Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

Launched by NATIONAL CANCER INSTITUTE (NCI) · Oct 31, 2022

Keywords

ClinConnect Summary

This is an observational study at the NIH Clinical Center to collect tumor tissue and blood from adults who are already having surgery or biopsy for known or suspected cancer. The goal is to learn more about how cancers differ from normal tissue and to understand the immune cells inside tumors, which could help identify new targets for future cancer treatments. Samples are collected to support research, not to provide a therapy in this study.

People 18 years and older with a known or suspected cancer that requires surgery or biopsy can be invited to participate, but they must agree to participate and sign consent. You’ll have a blood draw (including tests for HIV and hepatitis B/C) and tissue samples will be taken during procedures you would have anyway. The study lasts about 6 months and may involve additional blood tests or tissue samples if you have procedures during that time. No experimental drugs are given as part of this study. Your de-identified data, including genetic information, may be shared with other researchers, and genomic data may go to dbGaP. If you want more details, you can ask the study team or look up the NCT05600933 trial at the NIH Clinical Center in Bethesda, MD, led by Dr. Steven A. Rosenberg.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • Age \>= 18 years
• • Willing to undergo serologic testing for HIV, hepatitis B and C
• • Participants who have a known or suspected cancer that requires surgery or biopsy as a part of the standard of care diagnosis, treatment and/or follow up.
• • Note: Participants will not be enrolled exclusively for the procurement of tissue samples.
• • -Able and willing to sign an informed consent document.